Lv3
220 积分 2024-03-07 加入
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
3天前
已完结
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
6天前
已完结
Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials
9天前
已完结
How To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To Know
10天前
已完结
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
10天前
已完结
Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer
10天前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
11天前
已完结
Innovative, early-phase clinical trials of drug–radiotherapy combinations
18天前
已完结
Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis—Reply
18天前
已完结
Practical Updates and Diagnostic Challenges in Endometrial Carcinoma
19天前
已完结
皖公网安备34019202002308
